Why the study?
Does combined prophylaxis with ganciclovir and CMV hyperimmune globulin reduce CMV disease and improve survival in high-risk lung transplant recipients?
Does combined prophylaxis with ganciclovir and CMV hyperimmune globulin reduce CMV disease and improve survival in high-risk lung transplant recipients?
In high-risk lung transplant recipients, combined prophylaxis with ganciclovir and CMV hyperimmune globulin significantly reduces CMV disease and improves survival compared to ganciclovir alone.
Answers are grounded in this paper and cite their sources.
May support combined prophylaxis in high-risk lung recipients; leaves open need for randomized confirmation before practice change.
BACKGROUND: The benefit of cytomegalovirus (CMV) hyperimmune globuline in preventing CMV infection after lung transplantation still remains unclear. The aim of this study was to investigate the effect of combined prophylaxis using ganciclovir (GAN) and CMV hyperimmune globulin (CMV-IG) on CMV infection, CMV disease, survival and its role in preventing Bronchiolitis obliterans syndrome (BOS). METHODS: A consecutive series of 68 CMV high-risk lung transplant recipients (D+/R-, D+/R+), who had a minimum follow-up of 1 year posttransplant were analyzed. Thirty patients (44.1%) received single GAN prophylaxis for 3 months (control group) and 38 recipients (55.9%) received GAN together with CMV-IG 7 times during the first postoperative month (study group). Median follow-up was 16.5 months in the control and 23.8 months in the study group (P = 0.54). RESULTS: Five CMV-related deaths (16.7%) occurred in the control group (P = 0.014). Fifteen recipients suffered from CMV pneumonitis and three patients had CMV syndrome. In the control group, 13 recipients (43.3%) suffered from clinically manifested CMV disease compared to 5 (13.2%) in the study group (P = 0.007). Additionally, recipient survival was significantly better in the study group (P = 0.01). One year freedom from CMV affection was 52.1% in the control and 71.5% in the study group (P = 0.027). Three-year freedom from BOS was significantly higher in the study group (54.3% vs. 82%, P = 0.024). CONCLUSIONS: In CMV high risk patients, additional CMV-IG administration seems to be effective to reduce CMV-related morbidity and to avoid CMV-related mortality. Reduced incidence of BOS may result from improved CMV prevention, although randomized trials are warranted.
No takes yet. Share an insight, caveat, or question.
Ruttmann et al. (2006) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: